10-K: ZimVie Inc. Reports Full Year 2023 Results, Announces Sale of Spine Business

ZimVie Inc. reports a net loss for 2023, impacted by a significant write-down related to the sale of its spine business, while also highlighting growth in its dental segment.

Summary

• ZimVie Inc. reported a net loss of $393.3 million for the year ended December 31, 2023, which includes a $337.2 million loss from discontinued operations related to the sale of its spine business.
• The company's total net sales for 2023 were $457.4 million, a decrease of 1.3% compared to 2022.
• The dental segment experienced growth in digital dentistry and biomaterials, but this was partially offset by a decrease in dental implant sales.
• Operating expenses for 2023 were $488.4 million, a decrease from $509.8 million in 2022, due to cost reduction initiatives.
• Research and development expenses decreased to $26.2 million in 2023 from $31.1 million in 2022.
• The company incurred a $289.5 million write-down related to the sale of its spine business.
• ZimVie expects to use the net proceeds from the sale of the spine business to repay debt and invest in its dental business.
• The company anticipates continued growth in its dental product category, but also expects headwinds from foreign currency exchange risk and macroeconomic uncertainty.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with significant losses and a strategic shift, but also highlights growth potential in the dental segment. The sale of the spine business and restructuring efforts add uncertainty, resulting in a slightly negative sentiment.

Positives

• The company is focusing on its dental business, which is expected to drive growth and shareholder value.
• ZimVie anticipates continued growth in its dental product offerings, including implants, digital dentistry, and biomaterials.
• The company is implementing operational improvements to expand margins.
• ZimVie expects a decrease in interest expense in 2024 due to debt repayment using proceeds from the spine business sale.

Negatives

• The company reported a significant net loss of $393.3 million for 2023.
• Total net sales decreased by 1.3% compared to the previous year.
• The company experienced pricing pressures in North America and China.
• ZimVie is facing macroeconomic and inflationary pressures on its cost structure.
• The company incurred a substantial write-down of $289.5 million related to the sale of its spine business.

Risks

• The sale of the spine business is subject to various risks and may not be completed on the expected timeline or at all.
• The company may not achieve all the expected benefits from the sale of the spine business.
• ZimVie will be a smaller, less diversified company after the sale of the spine business.
• Interruption of manufacturing operations could adversely affect the business.
• Disruptions in the supply of materials or sterilization services could negatively impact operations.
• The company faces intense competition in the dental and spine markets.
• Restructuring initiatives may not be successful or may not fully realize expected cost savings.
• Failure to retain employees, agents, and distributors could lead to a decline in sales.
• If third-party payors decline to reimburse for products, demand may decline.
• The company is subject to cost containment measures and pricing pressures.
• Disruptions from the implementation of new enterprise resource planning systems could adversely impact operations.
• The company is exposed to risks from currency exchange rate fluctuations and inflation.
• There is a risk of excess and obsolete inventory.
• The company may have additional tax liabilities.
• Future material impairments in the carrying value of assets would negatively affect operating results.
• The company is subject to various legal, regulatory, and compliance risks.
• Failure to comply with data privacy and security laws could result in penalties.
• The company is increasingly dependent on sophisticated information technology and is vulnerable to cyberattacks.
• Pending and future product liability claims could adversely impact the company.
• Climate change and related measures may materially affect the company's operations.
• The company may not achieve all the expected benefits of the separation from Zimmer Biomet.
• The company may be required to pay under indemnification obligations to Zimmer Biomet.
• The allocation of intellectual property rights could adversely impact the company's competitive position.
• The market price of the company's common stock may be volatile.
• The company does not expect to pay any cash dividends for the foreseeable future.

Future Outlook

ZimVie expects continued growth in its dental product category, but also anticipates headwinds from foreign currency exchange risk and macroeconomic uncertainty. The company plans to focus on operational improvements and debt reduction.

Management Comments

• Management is focused on driving operational improvements to optimize the business and expand margins.
• The company believes that focusing on its dental business will drive growth and shareholder value.
• Management expects an overall decrease in interest expense in 2024 as a result of debt repayment.

Industry Context

The medical technology industry is highly competitive, with companies constantly innovating and introducing new products. ZimVie's sale of its spine business and focus on dental aligns with a trend of companies streamlining their portfolios to focus on core growth areas. The company faces competition from major players in both the dental and spine markets, including Straumann, Dentsply Sirona, Medtronic, and Johnson & Johnson.

Comparison to Industry Standards

• ZimVie's performance is mixed when compared to industry standards.
• While the company is experiencing growth in certain areas of its dental business, the overall revenue decline and significant net loss are concerning.
• Competitors like Straumann and Dentsply Sirona in the dental market have shown more consistent revenue growth and profitability.
• In the spine market, companies like Medtronic and Johnson & Johnson have larger market shares and more diversified portfolios.
• ZimVie's decision to sell its spine business and focus on dental is a strategic move that may improve its long-term performance, but it also carries risks.
• The company's restructuring efforts and cost reduction initiatives are necessary to improve profitability and compete effectively in the market.

Related Party Transactions

• Prior to the distribution, ZimVie had various relationships with Zimmer Biomet, including corporate overhead allocations and manufacturing services.
• Following the distribution, ZimVie entered into various agreements with Zimmer Biomet, including a Transition Services Agreement and transition manufacturing agreements.
• As of February 1, 2023, Zimmer Biomet is no longer considered a related party.

Stakeholder Impact

• Shareholders will be impacted by the net loss and the strategic shift to focus on the dental business.
• Employees may be affected by restructuring activities and changes in the company's focus.
• Customers may experience changes in product offerings and services due to the sale of the spine business.
• Suppliers may be impacted by changes in the company's supply chain and manufacturing operations.
• Creditors will be impacted by the company's debt repayment plans.

Next Steps

• The company expects to close the sale of its spine business in the first half of 2024.
• ZimVie plans to use the proceeds from the sale to repay debt and invest in its dental business.
• The company will continue to focus on operational improvements and cost reduction initiatives.
• ZimVie will continue to develop and launch new products in its dental segment.

Key Dates

Keywords

dental implants, spine surgery, medical technology, biomaterials, digital dentistry, cervical disc replacement, vertebral body tethering, restructuring, discontinued operations, cost reduction, regulatory approvals, intellectual property, cybersecurity, reimbursement, product liability